Trial Profile
A Phase I Dose Escalation Study of MK1775 in Monotherapy, in Combination With 5-Fluorouracil, and in Combination With 5-Fluorouracil and Cisplatin in Patients With Advanced Solid Tumor
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Cisplatin; Fluorouracil
- Indications Gastric cancer; Head and neck cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 23 Jun 2011 Planned end date changed from 1 Jun 2013 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 23 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 May 2010 Planned end date changed from 1 Jul 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.